当前位置: X-MOL 学术Front. Vet. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Evaluating the Feasibility and Efficacy of a Dual-Modality Nanoparticle Contrast Agent (Nanotrast-CF800) for Image-Guided Sentinel Lymph Node Mapping in the Oral Cavity of Healthy Dogs
Frontiers in Veterinary Science ( IF 3.2 ) Pub Date : 2021-09-23 , DOI: 10.3389/fvets.2021.721003
Jennifer Wan 1 , Michelle L Oblak 1 , Ann S Ram 2 , Charly McKenna 1, 2 , Ameet Singh 1 , Stephanie Nykamp 1
Affiliation  

A combination of pre and intraoperative sentinel lymph node (SLN) mapping techniques have been suggested to optimize SLN detection. A novel liposomal nanoparticle, Nanotrast-CF800 (CF800), utilizes computed tomography lymphography (CTL) and near infrared fluorescence imaging (NIRF) for image-guided surgery and SLN mapping. This novel tracer agent has not been evaluated in companion animals. The objective of this study was to evaluate the feasibility and efficacy of CF800 for SLN mapping in the oral cavity of healthy dogs and to report any local adverse effects. Six healthy adult purpose-bred research dogs randomly received either 1 mL (group 1) or 2 mL (group 2) of CF800 injected into the submucosa at the level of the right canine maxillary tooth. CTL and percutaneous NIRF were performed at 1, 3, and 10 min, then 1, 2, 4, 7, and 10 days post-injection (p.i). Overall, both CTL and NIRF identified SLNs in all dogs. The overall peak mean contrast enhancement of the SLNs was 73.98 HU (range 63.45–86.27 HU) at 2 days p.i. Peak fluorescence of the SLN occurred at 1 day p.i. The agent was retained within the SLN for at least 7 days for CTL and 4 days for percutaneous NIRF. No adverse effects were observed. Local administration of CF800 was simple and feasible for the detection of SLNs using CTL+NIRF in the head and neck of healthy dogs and was not associated with significant local adverse events.



中文翻译:

评估双模态纳米颗粒造影剂 (Nanotrast-CF800) 用于健康犬口腔图像引导前哨淋巴结映射的可行性和有效性

已建议结合术前和术中前哨淋巴结 (SLN) 映射技术来优化 SLN 检测。一种新型脂质体纳米颗粒 Nanotrast-CF800 (CF800) 利用计算机断层扫描淋巴成像 (CTL) 和近红外荧光成像 (NIRF) 进行图像引导手术和 SLN 映射。这种新型示踪剂尚未在伴侣动物中进行评估。本研究的目的是评估 CF800 在健康犬口腔中进行 SLN 定位的可行性和有效性,并报告任何局部不良反应。六只健康成年目的繁殖研究犬随机接受 1 mL(第 1 组)或 2 mL(第 2 组)CF800 注射到右侧犬上颌牙水平的粘膜下层。CTL 和经皮 NIRF 在 1、3 和 10 分钟时进行,然后在 1、2、4、7、和注射后 10 天 (pi)。总体而言,CTL 和 NIRF 都在所有狗中鉴定了 SLN。注射后第 2 天 SLN 的整体峰值平均对比度增强为 73.98 HU(范围 63.45–86.27 HU) 注射后第 1 天出现 SLN 的峰值荧光 药剂在 SLN 内保留至少 7 天 CTL 和 4 天用于经皮 NIRF。没有观察到不良反应。CF800 的局部给药对于使用 CTL+NIRF 在健康犬的头颈部检测 SLN 简单可行,并且与显着的局部不良事件无关。药剂在 SLN 内保留至少 7 天 CTL 和 4 天经皮 NIRF。没有观察到不良反应。CF800 的局部给药对于使用 CTL+NIRF 在健康犬的头颈部检测 SLN 简单可行,并且与显着的局部不良事件无关。药剂在前哨淋巴结内保留至少 7 天的 CTL 和 4 天的经皮 NIRF。没有观察到不良反应。CF800 的局部给药对于使用 CTL+NIRF 在健康犬的头颈部检测 SLN 简单可行,并且与显着的局部不良事件无关。

更新日期:2021-09-23
down
wechat
bug